Application of VEGF-C (vascular endothelial growth factor-C)/VEGFR-3 (vascular endothelial growth factor receptor-3 signal medicated lyphangion genesis to prevention and treatment of cardiac failure

A 1. VEGF-C, heart failure technology, applied in the field of lymphangiogenesis, can solve problems such as adverse reactions

Inactive Publication Date: 2018-08-28
FIRST AFFILIATED HOSPITAL OF DALIAN MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The specific application of recombinant human VEGF-C described in the present invention can not only solve the problem of adverse reactions caused by traditional clinical application of related drugs to treat heart failure, but also provide a new important mechanism for the occurrence and development of heart failure (VEGF-C / Lymphangiogenesis mediated by VEGFR-3 signal), which provides new ideas and solutions for the prevention and treatment of heart failure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of VEGF-C (vascular endothelial growth factor-C)/VEGFR-3 (vascular endothelial growth factor receptor-3 signal medicated lyphangion genesis to prevention and treatment of cardiac failure
  • Application of VEGF-C (vascular endothelial growth factor-C)/VEGFR-3 (vascular endothelial growth factor receptor-3 signal medicated lyphangion genesis to prevention and treatment of cardiac failure
  • Application of VEGF-C (vascular endothelial growth factor-C)/VEGFR-3 (vascular endothelial growth factor receptor-3 signal medicated lyphangion genesis to prevention and treatment of cardiac failure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0018] The specific embodiments of the present invention will be described below in conjunction with the drawings. It should be understood that the preferred embodiments described here are only used to illustrate and explain the present invention, but not to limit the present invention. Such as Figure 1 to Figure 7 Shown:

[0019] In order to better understand the essence of the present invention, mice will be used as a test to illustrate its new use in the pharmaceutical field.

[0020] Establish a TAC-induced heart failure model in mice: Take 6-8 week old SPF male C57BL / 6 mice, sterilize the surgical area with 75% alcohol after anesthesia, cut the skin from the neck to the second intercostal space of the sternum, separate the muscles and expose them Cut the trachea and sternum from the middle from the stem of the sternum to the sternum connecting the second intercostal space. Use a chest retractor to open the chest cavity to separate the thymus and fat tissue from the aorta; ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to new application of VEGF-C (vascular endothelial growth factor-C)/VEGFR-3 (vascular endothelial growth factor receptor-3 signal medicated lyphangion genesis, in particular to the application of VEGF-C/VEGFR-3 signal medicated lyphangion genesis to prevention and treatment of cardiac failure. According to the specific application of recombinant human VEGF-C, the adverse reaction problem caused by the fact that in the traditional clinical application, the related medicine is used for treating cardiac failure can be solved, new important mechanism (VEGF-C/VEGFR-3 signal medicated lyphangion genesis) is provided for genesis and development of the cardiac failure, and new thought and scheme are provided for preventing and treating the cardiac failure.

Description

Technical field [0001] The present invention relates to a new use of VEGF-C / VEGFR-3 signal-mediated lymphangiogenesis, in particular to the application of VEGF-C / VEGFR-3 signal-mediated lymphangiogenesis in the prevention and treatment of heart failure. Background technique [0002] Heart failure (abbreviated as heart failure) is due to abnormalities in the structure and / or function of the heart that cause a reduction in cardiac output and / or an increase in intracardiac pressure at rest or under load, leading to one of the typical symptoms (dyspnea, ankle edema, fatigue, etc.) Kind of clinical syndrome. Heart failure is the severe and terminal stage of various cardiovascular diseases, such as hypertension, coronary heart disease, cardiomyopathy, left ventricular hypertrophy, valvular disease, myocardial hypoxia, and cardiac toxicants, etc., and its morbidity and mortality are high , Has become one of the most important cardiovascular diseases today. [0003] Current studies have ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/18A61K38/17A61K45/00A61P9/04
CPCA61K38/1866A61K38/179A61K45/00
Inventor 李汇华林秋月白洁严啸张云龙刘莹夏云龙
Owner FIRST AFFILIATED HOSPITAL OF DALIAN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap